000 02546cam  2200349za 4500
0019.833902
003CaOODSP
00520221107150321
007cr |||||||||||
008170320s2017    onc    #ob   f000 0 eng d
020 |a978-0-660-08004-8
040 |aCaOODSP|beng
043 |an-cn---
0861 |aHP40-157/2017E-PDF
24500|aUpdated recommendations on human papillomavirus (HPV) vaccines |h[electronic resource] : |b9-valent HPV vaccine and clarification of minimum intervals between doses in the HPV immunization schedule.
2461 |iAt head of title: |aAdvisory committee statement (ACS) - National Advisory Committee on Immunization (NACI)
24630|a9-valent HPV vaccine and clarification of minimum intervals between doses in the HPV immunization schedule
260 |a[Ottawa] : |bPublic Health Agency of Canada, |c2017.
300 |a55 p.
500 |aIssued also in HTML format.
500 |aIssued also in French under title: Recommandations mises à jour sur les vaccins contre le virus du papillome humain (VPH) : vaccin nonavalent contre le VPH et précisions sur les intervalles minimums entre les doses dans le calendrier d'immunisation contre le VPH.
504 |aIncludes bibliographical references.
520 |a"In February 2015, a nine-valent human papillomavirus vaccine (HPV9) (Gardasil®9, Merck Canada, Inc.) was authorized for use in Canada. The purpose of this statement is to summarize information on this vaccine and to provide evidence-based recommendations on its use in the context of recommendations for all HPV vaccines currently authorized for use in Canada. In addition, this statement will clarify minimum intervals between doses of HPV vaccines for two-dose and three-dose HPV immunization schedules"--Introduction, p. 7.
69207|2gccst|aSexually transmitted diseases
69207|2gccst|aImmunization
7101 |aCanada. |bNational Advisory Committee on Immunization.
7102 |aPublic Health Agency of Canada.
77508|tRecommandations mises à jour sur les vaccins contre le virus du papillome humain (VPH) |w(CaOODSP)9.833903
795 |tUpdated recommendations on human papillomavirus (HPV) vaccines |w(CaOODSP)9.818011
85640|qPDF|s1.18 MB|uhttps://publications.gc.ca/collections/collection_2017/aspc-phac/HP40-157-2017-eng.pdf
8564 |qHTML|sN/A|uhttps://www.canada.ca/en/public-health/services/publications/healthy-living/9-valent-hpv-vaccine-clarification-minimum-intervals-between-doses-in-hpv-immunization-schedule.html